Trial Profile
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Tenofovir disoproxil fumarate
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.
- 24 Aug 2017 New trial record